Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
17 févr. 2022 08h00 HE
|
Arvinas Inc.
– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA50 rate and durable RECIST responses – – Data support the...
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
14 févr. 2022 18h04 HE
|
Arvinas Inc.
– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to...
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
08 févr. 2022 08h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Arvinas to Present at Upcoming Investor Conferences
03 févr. 2022 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program
03 févr. 2022 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
13 janv. 2022 07h00 HE
|
Salarius Pharmaceuticals, Inc.
Transformative acquisition significantly expands Salarius’ oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area...
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
10 déc. 2021 08h10 HE
|
Arvinas Inc.
– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium – – ARV-471 is...
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
19 nov. 2021 09h55 HE
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose...
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
10 nov. 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
03 nov. 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...